OncoMatch/Clinical Trials/NCT05769010
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Is NCT05769010 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including SHR-A1811 and Pyrotinib for metastatic breast cancer.
Treatment: SHR-A1811 · Pyrotinib · Bevacizumab · Adebelizumab — This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) expression
HER2-positive or HER2-low advanced breast cancer
Demographics
Prior therapy
Cannot have received: antibody-drug conjugate (exatecan derivative, topoisomerase 1 inhibitor) (trastuzumab deruxtecan)
Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05769010 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody-drug conjugate (exatecan derivative, topoisomerase 1 inhibitor) disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages